CelLBxHealth plc
ANPCY · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.06 | 0.13 | -0.19 | -8.07 |
| FCF Yield | -43.66% | -48.57% | -14.03% | -5.67% |
| EV / EBITDA | -1.97 | -1.02 | -4.14 | -15.84 |
| Quality | ||||
| ROIC | -61.96% | -72.61% | -47.44% | -34.71% |
| Gross Margin | 62.16% | -18.66% | 58.89% | 70.19% |
| Cash Conversion Ratio | 0.89 | 0.67 | 0.66 | 0.81 |
| Growth | ||||
| Revenue 3-Year CAGR | 40.09% | 29.23% | 10.96% | 5.14% |
| Free Cash Flow Growth | 8.11% | 15.72% | -13.54% | -89.11% |
| Safety | ||||
| Net Debt / EBITDA | 0.48 | 0.61 | 1.10 | 1.88 |
| Interest Coverage | -49.17 | -66.95 | -68.38 | -109.78 |
| Efficiency | ||||
| Inventory Turnover | 0.69 | 1.54 | 0.21 | 0.17 |
| Cash Conversion Cycle | 527.24 | 208.63 | 601.60 | 846.77 |